Semax and Selank: BDNF Modulation in Research Models

Semax and Selank are two synthetic neuropeptides developed in the Russian research programme and frequently ordered together for cognitive research protocols. They share almost nothing at the chemical level: Semax is a synthetic analogue of the ACTH(4-10) fragment, Selank is a synthetic analogue of the natural tetrapeptide tuftsin. What they share is a downstream effect on BDNF (brain-derived neurotrophic factor) expression in the hippocampus, which has become the unifying research story for the pair.

This article walks through the BDNF biology each compound engages, the primary literature documenting the effect in rat models, and what’s well-established vs still exploratory about the translational implications.

Why BDNF is the unifying story

BDNF is the most-studied neurotrophic factor in adult central nervous system research. It regulates synaptic plasticity, supports neuronal survival under stress, drives adult hippocampal neurogenesis, and modulates the strength of excitatory synapses. Low BDNF signalling has been implicated in depression, neurodegenerative disease, cognitive decline, and stress-related disorders. Elevating BDNF pharmacologically has therefore been a research goal for decades.

Colucci-D’Amato and colleagues’ 2020 International Journal of Molecular Sciences review ⁶ is the best modern reference for BDNF’s physiological functions and therapeutic potential. The review covers the depression, neurodegeneration, and brain cancer contexts, and lays out the multiple signalling pathways (TrkB receptor activation → PI3K/Akt, MAPK, PLCγ) that translate BDNF binding into downstream neurotrophic effects.

Semax and Selank both elevate BDNF in research models, but through entirely different upstream mechanisms. That convergence on a shared downstream signal is what makes them a natural research pair.

Semax: the ACTH(4-10) → BDNF pathway

Semax is a synthetic heptapeptide analogue of the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro extension that confers resistance to proteolysis and extends central-nervous-system exposure. The parent ACTH(4-10) sequence is the minimum fragment of corticotropin that retains the neurotropic effects of the full hormone without the adrenal-stimulating HPA-axis activity. Semax inherits this neurotropic selectivity.

The primary BDNF evidence

Dolotov and colleagues’ 2006 Brain Research paper is the foundational Semax BDNF reference ¹. The study used intranasal Semax administration in rats and measured BDNF and TrkB (BDNF’s high-affinity receptor) expression in the hippocampus at multiple time points post-administration. Key findings:

• BDNF mRNA elevation peaked at ~4 hours post-Semax administration
• BDNF protein elevation peaked at ~24 hours, lagging the mRNA signal
• TrkB receptor upregulation ran in parallel with the BDNF increase
• Effects were dose-dependent at research-relevant Semax concentrations

The time-course pattern matters for protocol design: BDNF response to a single Semax dose persists for roughly 24-48 hours, and chronic dosing (2-3 times daily) maintains an elevated steady-state signal.

Replication and extension

Three follow-on papers expanded the Dolotov 2006 findings:

Agapova 2007 (Neurosci Lett) ⁴ examined neurotrophin gene expression in rat brain more broadly under Semax action, confirming the BDNF/NGF pattern in hippocampus and extending to frontal cortex.

Agapova 2008 (Mol Gen Mikrobiol Virusol) ³ added finer time-course analysis of the BDNF and NGF gene expression dynamics in hippocampus and frontal cortex. The temporal pattern was consistent with Dolotov 2006 but added regional detail (frontal cortex showed a smaller and delayed response compared to hippocampus).

Shadrina 2010 (J Mol Neurosci) ² compared the BDNF and NGF dynamics across three tissues (hippocampus, frontal cortex, and retina) under Semax administration. The hippocampus response was largest; frontal cortex was intermediate; retina showed a distinct pattern that may reflect intranasal delivery depositing peptide closer to retinal tissue than to deeper brain regions.

The pattern across all four papers: Semax reliably elevates BDNF and NGF in rat hippocampus, with a characteristic time-course, in a dose-dependent manner. This is one of the more replicated findings in the neuropeptide research literature, albeit replicated primarily within the Russian research programme.

Upstream mechanism: still partly characterised

How Semax reaches BDNF expression changes is less well-mapped than the downstream effect itself. Proposed upstream steps:

• Melanocortin receptor engagement. The ACTH(4-10) parent sequence binds melanocortin receptors (MC3R, MC4R, MC5R). Semax retains some of this binding but at reduced affinity; whether melanocortin signalling drives the BDNF response is debated.
• Direct CNS penetration via intranasal delivery. Intranasal administration allows peptide to reach brain tissue via olfactory and trigeminal pathways, bypassing the blood-brain barrier’s exclusion of peptides.
• Secondary cascades through cAMP-responsive transcription. BDNF transcription is regulated partly by CREB binding to the BDNF promoter; several peptide signalling pathways converge on CREB activation and could plausibly drive the observed BDNF elevation.

The upstream pathway is the part of Semax pharmacology most actively under investigation; the downstream BDNF effect is the part that’s settled.

Selank: the tuftsin → BDNF pathway

Selank is a synthetic heptapeptide analogue of the natural tetrapeptide tuftsin, with an N-terminal extension that confers proteolytic stability. Tuftsin is an immunoregulatory peptide derived from IgG; Selank’s additional residues shift the pharmacology from immune-focused to neuro-focused.

The primary BDNF evidence

The Selank BDNF evidence is thinner than Semax’s but directionally consistent. Kolomin and colleagues’ broader work on synthetic peptides based on natural regulatory peptides ⁵ covers the transcriptomic framework within which Selank’s BDNF elevation was characterised. The approach used genome-wide transcript profiling in rat hippocampus and spleen after Selank administration, identifying upregulated gene clusters that included BDNF and related neurotrophic factors.

The transcriptomic approach has strengths (comprehensive, unbiased gene discovery) and weaknesses (requires direct protein-level confirmation to establish biological significance). For Selank, the protein-level confirmation is limited; the BDNF elevation claim rests primarily on transcriptomic data rather than the direct protein measurement Dolotov used for Semax.

Upstream mechanism: enkephalinergic and GABAergic

Selank’s upstream pharmacology involves modulation of enkephalinergic and GABAergic systems, which matters for the anxiolytic research endpoint but is less directly tied to BDNF than Semax’s ACTH-derived pathway:

• Enkephalin interaction. Selank affects the activity of enkephalin-degrading peptidases, effectively extending enkephalin signalling duration. Enkephalin signalling has complex CNS effects including anxiety modulation.
• GABAergic modulation. Selank influences GABA-related pathways in ways that produce its anxiolytic effect without the sedation or dependence liability of benzodiazepines.
• Indirect BDNF elevation. BDNF response to Selank may be downstream of these GABAergic and enkephalinergic changes rather than a direct Selank → BDNF pathway, which would explain why the protein-level BDNF signal is less robust than Semax’s.

Why the Semax + Selank combination makes biological sense

For cognitive research protocols that want both BDNF elevation and stress/anxiety modulation, the Semax + Selank combination is mechanistically coherent:

• Semax provides the primary BDNF signal through the well-characterised ACTH(4-10) pathway
• Selank provides the anxiolytic effect through GABAergic/enkephalinergic modulation, with a secondary BDNF contribution
• Neither compound competes for the same receptor system. Semax’s melanocortin-adjacent signalling and Selank’s GABA-adjacent signalling are pharmacologically independent
• Intranasal delivery is common to both. Protocol operationally: alternate nostrils, 2-3 times daily for Semax, 2 times daily for Selank. Easy scheduling.

The combination is not additive in a simple dose-response sense; each compound contributes its own axis, and the combined protocol produces a more complete pharmacological state than either compound alone.

Translation questions that remain open

Three questions the primary literature does not fully answer:

1. Does BDNF elevation in research models translate to human cognitive enhancement?

BDNF elevation in rat hippocampus is a well-established Semax effect. Whether the pharmacologically elevated BDNF produces clinically meaningful cognitive improvement in humans is less certain. Russian clinical use of Semax is primarily for ischaemic stroke recovery, where the mechanism is plausibly neuroprotective (supporting survival of neurons in the peri-infarct penumbra) rather than cognitive-enhancing. Western trials designed specifically to test cognitive endpoints at research doses have not been widely conducted.

2. How does BDNF response change with chronic dosing?

Most BDNF research in rats uses acute or sub-chronic dosing (single doses up to 14 days). Chronic dosing (weeks to months) is used in human research and clinical practice but has less published data on BDNF response kinetics. Whether BDNF elevation sustains at chronic dose levels, or whether receptor desensitisation or negative feedback attenuates the response over time, is not well-characterised.

3. What’s the role of the ACTH(4-10) residues vs the Pro-Gly-Pro extension?

Semax’s distinctive stability vs native ACTH(4-10) comes from the C-terminal extension. Whether the extension is purely a pharmacokinetic modification (slowing degradation) or also contributes to the BDNF-driving activity is an open question. Dolotov 2006 established the full Semax sequence as the active compound; whether the ACTH(4-10) core alone would show similar BDNF effects at equivalent exposure has not been directly tested.

Research protocol considerations

For researchers using Semax or Selank in BDNF-focused protocols:

1. Use intranasal delivery, match published dose ranges. 250-500 µg per dose, 2-3 times daily (Semax) or 2 times daily (Selank). Deviating from these ranges exits the research-supported dose space.
2. Cycle 14 days on, 14 days off, mirroring Russian clinical practice. This is the pattern under which the BDNF effects have been characterised; continuous dosing beyond this has limited published data.
3. Track anxiety/stress measures alongside cognitive measures. Selank’s primary endpoint is anxiolytic; if the research protocol doesn’t measure this axis, Selank’s contribution is underestimated.
4. Consider the combination for dual-endpoint protocols. Semax alone for pure cognitive research; Selank alone for pure anxiolytic research; Semax + Selank for protocols spanning both.

See the broader nootropic peptide mechanisms deep-dive for receptor-level comparison across the class, and the best peptides for cognitive function buyer-intent comparison for ordering decisions.

Where to order

Buy Semax and buy Selank from Thailand Peptides through the Bangkok research desk. Intranasal research solutions, ≥98% HPLC purity, supplier COA on file, same-week Thailand delivery. For combined-order pricing on the Semax + Selank pairing, WhatsApp the research desk directly.

For the wider nootropic-peptide research landscape including Cerebrolysin and DSIP, see best peptides for cognitive function. For the receptor-level mechanism comparison across the class, see nootropic peptide mechanisms.